Vertex Launching 3-Month Study of Incivek
Share
Follow Us
Vertex study will evaluate 12-week treatment period for some hepatitis C patients
10/24/11
By Chris Reidy, Globe Staff
Five months after it received regulatory approval for a potential blockbuster hepatitis C drug called Incivek, Vertex Pharmaceuticals Inc. said it is launching a study to evaluate whether some patients can benefit from 12 weeks of treatment rather than 24 or 48 weeks.
Incivek is currently being used as a component in a drug combination therapy that stretches from 24 to 48 weeks, but there is a subset of hepatitis C patients who tend to respond more quickly to treatment, and Cambridge-based Vertex said in a press release that is is now looking to evaluate the effectiveness of a 12-week treatment period for that patient group.
Continue reading this entire article:
http://www.boston.com/Boston/businessupdates/2011/10/vertex-study-will-evaluate-week-treatment-period-for-some-hepatitis-patients/4sotlXUEQLVJnlFp6jxnRI/index.html
